```
VS T GONDII MAC UP, GSE360 CTRL VS T GONDII MAC UP
```

```
GSE42021_CD24LO_TREG_VS_CD24LO_TCONV_THYMUS_DN, GSE42021_CD24LO_TREG_VS_CD24LO_TCONV_THYMUS_DN
 GSE23114 PERITONEAL CAVITY B1A BCELL VS SPLEEN BCELL IN SLE2C1 MOUSE UP, GSE23114 PERITONEAL CAVITY B1A BCELL VS SPLEEN BCELL IN SLE2C1 MOUSE UP
✓ GSE1448_CTRL_VS_ANTI_VALPHA2_DP_THYMOCYTE_UP, GSE1448_CTRL_VS_ANTI_VALPHA2_DP_THYMOCYTE_UP
 GSE28726_NAIVE_CD4_TCELL_VS_NAIVE_VA24NEG_NKTCELL_DN, GSE28726_NAIVE_CD4_TCELL_VS_NAIVE_VA24NEG_NKTCELL_DN
 GSE42021 CD24INT VS CD24LOW TREG THYMUS UP, GSE42021 CD24INT VS CD24LOW TREG THYMUS UP
 HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN, HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN, HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN, HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN, HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN, HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN, HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN, HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN, HARALAMBIEVA_PBMC_M_R_II_AGE_11_122YO_VACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN, HARALAMBIEVA_TREATMENT_7YR_DN, HARALAMBIEVA_TREATMENT_7YR_DN, HARALAMBIEVA_TREATMENT_7YR_DN, HARALAMBIEVA_TREATMENT_7YR_DN, HARALAMBIEVA_TREATMENT_7YR_DN, HARALAMBIEVA_TREATMENT
```

HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED VS UNVACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M M R II AGE 11 22YO VACCINATED HIGH ANTIBODY RESPONDERS TO TREATMENT 7YR DN, HARALAMBIEVA PBMC M R TREATMEN

GSE34217 MIR17 92 OVEREXPRESS VS WT ACT CD8 TCELL DN, GSE34217 MIR17 92 OVEREXPRESS VS WT ACT CD8 TCELL DN